Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03152292 · ClinicalTrials.gov registry record
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
A clinical trial, sponsored by ACADIA Pharmaceuticals.
- Terminated
- Registry status
- 764
- Enrollment target
NCT03152292 is a clinical trial that was terminated before completion, run by ACADIA Pharmaceuticals. The registered enrollment target is 764 participants.
The verdict
NCT03152292 was terminated before completion, sponsored by ACADIA Pharmaceuticals.
- TERMINATED
- Registry status
- 764 participants
- Enrollment target
Study Summary
To examine the current disease progression of PDP, the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers
Interventions
- OTHER Real-world, non-interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 764 participants |
| Start Date | 2017-03-30 |
| Est. Completion | 2021-03-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03152292
The ClinicalTrials.gov registry entry for NCT03152292 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 764 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Real-world, non-interventional is the first listed.
NCT03152292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03152292 about?
NCT03152292 is a clinical study titled "The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study". To examine the current disease progression of PDP, the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers
What is the current status of trial NCT03152292?
This trial is currently terminated. The enrollment target is 764 participants. The study started on 2017-03-30. Estimated completion is 2021-03-08.
What interventions are being tested in trial NCT03152292?
The interventions under investigation include: Real-world, non-interventional (OTHER).
Who is sponsoring clinical trial NCT03152292?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.